Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astrazeneca Ord Shs AZNCF

Healthcare
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex... see more

Recent & Breaking News (OTCPK:AZNCF)

Net Asset Value(s)

UK Regulatory news services, from the LSE May 27, 2016

Positive results from AstraZeneca Faslodex trial

UK Regulatory news services, from the LSE May 27, 2016

Total Voting Rights

Hugin May 27, 2016

AstraZeneca receives CRL from US FDA for ZS-9

UK Regulatory news services, from the LSE May 27, 2016

Appointment of Chief Executive Officer

UK Regulatory news services, from the LSE May 27, 2016

AstraZeneca's Fulvestrant Met Its Primary Endpoint as First-Line Treatment in a Phase III Trial for HR+ Advanced Breast Cancer

Business Wire May 27, 2016

POSITIVE CHMP OPINION IN EU FOR SAXA/DAPA

UK Regulatory news services, from the LSE May 27, 2016

Form 8.5 (EPT/RI)Replacement Darty Plc

UK Regulatory news services, from the LSE May 27, 2016

Form 8.5 (EPT/RI)Replacement Anheuser-Busch InBev

UK Regulatory news services, from the LSE May 27, 2016

Net Asset Value Weekly to 20 May 2016

UK Regulatory news services, from the LSE May 27, 2016

Form 8.3 - Groupe Fnac

UK Regulatory news services, from the LSE May 27, 2016

Form 8.5 (EPT/NON-RI) London Stock Exchange

UK Regulatory news services, from the LSE May 27, 2016

Form 8.5 (EPT/RI) London Stock Exchange

UK Regulatory news services, from the LSE May 27, 2016

Form 8.5 (EPT/RI) Deutsche Borse AG

UK Regulatory news services, from the LSE May 27, 2016

Form 8.5 (EPT/RI) Ball Corp

UK Regulatory news services, from the LSE May 27, 2016

Form 8.5 (EPT/RI) Anheuser-Busch

UK Regulatory news services, from the LSE May 27, 2016

Form 8.5 (EPT/NON-RI) SABMiller Plc

UK Regulatory news services, from the LSE May 27, 2016

GEM Notice

UK Regulatory news services, from the LSE May 27, 2016

Director/PDMR Shareholding

UK Regulatory news services, from the LSE May 23, 2016

Net Asset Value(s)

UK Regulatory news services, from the LSE May 23, 2016